Comments
yourfanat wrote: I am using another tool for Oracle developers - dbForge Studio for Oracle. This IDE has lots of usefull features, among them: oracle designer, code competion and formatter, query builder, debugger, profiler, erxport/import, reports and many others. The latest version supports Oracle 12C. More information here.
Cloud Expo on Google News
SYS-CON.TV
Cloud Expo & Virtualization 2009 East
PLATINUM SPONSORS:
IBM
Smarter Business Solutions Through Dynamic Infrastructure
IBM
Smarter Insights: How the CIO Becomes a Hero Again
Microsoft
Windows Azure
GOLD SPONSORS:
Appsense
Why VDI?
CA
Maximizing the Business Value of Virtualization in Enterprise and Cloud Computing Environments
ExactTarget
Messaging in the Cloud - Email, SMS and Voice
Freedom OSS
Stairway to the Cloud
Sun
Sun's Incubation Platform: Helping Startups Serve the Enterprise
POWER PANELS:
Cloud Computing & Enterprise IT: Cost & Operational Benefits
How and Why is a Flexible IT Infrastructure the Key To the Future?
Click For 2008 West
Event Webcasts
Novel Cancer Immune Therapy Developer Oncos Therapeutics Ltd. Appoints Experienced Industry Leader Frans Wuite as President and CEO

HELSINKI, November 9, 2012 /PRNewswire/ --

Oncos Therapeutics Ltd., a company developing novel cancer immune therapeutics, announced today that it has appointed Frans Wuite, M.D., M.B.A, as President and Chief Executive Officer and Pekka Simula, M.Sc. (Tech) as Chief Operating Officer.

Frans Wuite brings more than 25 years of leadership experience that spans from start-up to large international companies within the biopharmaceutical industry to Oncos Therapeutics. Prior to joining Oncos, Wuite served in key leadership roles at companies in rapid growth phases. These included Amgen Europe, where he spearheaded the commercial development and launch of Aranesp that soon became Amgen's biggest product.

Pekka Simula, the founding CEO of Oncos since 2008, successfully built Oncos into a clinical stage company. In his role as COO, Simula will be responsible for the company's overall program management covering research, clinical development, process development, and manufacturing.

Prior to Oncos, Simula was Global Program Manager at Varian Medical Systems responsible for the development and market roll-out of the company's entire oncology product suite.  

About Oncos Therapeutics

Oncos Therapeutics develops personalized cancer immunotherapeutics based on its proprietary oncolytic adenovirus technology. The Company has clinical experience on 10 purposefully engineered vaccines. These have a direct oncolytic effect due to selective virus replication in tumor cells, systemic effects through vascular dissemination to metastases, and induction of a strong immune response against tumor cells mediated by exposure of tumor antigens upon oncolysis. In addition, most of Oncos product candidates have a transgene that result in cytokine production in only cancer cells, e.g. GM-CSF, further enhancing the immune response against tumor cells. Oncos' oncolytic vaccine portfolio will be focused on carefully selected cancer types that respond poorly to conventional therapies.

Based on efficacy and safety signals obtained in an Advanced Therapy Access Program (ATAP) with 290 cancer patients, for whom standard of care therapies had failed, CGTG-102 was selected as Oncos' lead product. Clinical experience with 115 CGTG-102-treated patients in ATAP has yielded important information on e.g. optimal dosing and scheduling of the product. CGTG-102 has an orphan indication as its initial target: first line treatment of inoperable Soft Tissue Sarcoma. It is currently in Phase 1 clinical development in Europe and the US. For more information, see http://www.oncos.com.

SOURCE Oncos Therapeutics

About PR Newswire
Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Cloud Developer Stories
SYS-CON Events announced today that Venafi, the Immune System for the Internet™ and the leading provider of Next Generation Trust Protection, will exhibit at @DevOpsSummit at 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention...
Security, data privacy, reliability, and regulatory compliance are critical factors when evaluating whether to move business applications from in-house, client-hosted environments to a cloud platform. Quality assurance plays a vital role in ensuring that the appropriate level of ...
It’s 2016: buildings are smart, connected and the IoT is fundamentally altering how control and operating systems work and speak to each other. Platforms across the enterprise are networked via inexpensive sensors to collect massive amounts of data for analytics, information mana...
"We formed Formation several years ago to really address the need for bring complete modernization and software-defined storage to the more classic private cloud marketplace," stated Mark Lewis, Chairman and CEO of Formation Data Systems, in this SYS-CON.tv interview at 18th Clou...
Deploying applications in hybrid cloud environments is hard work. Your team spends most of the time maintaining your infrastructure, configuring dev/test and production environments, and deploying applications across environments – which can be both time consuming and error prone...
Subscribe to the World's Most Powerful Newsletters
Subscribe to Our Rss Feeds & Get Your SYS-CON News Live!
Click to Add our RSS Feeds to the Service of Your Choice:
Google Reader or Homepage Add to My Yahoo! Subscribe with Bloglines Subscribe in NewsGator Online
myFeedster Add to My AOL Subscribe in Rojo Add 'Hugg' to Newsburst from CNET News.com Kinja Digest View Additional SYS-CON Feeds
Publish Your Article! Please send it to editorial(at)sys-con.com!

Advertise on this site! Contact advertising(at)sys-con.com! 201 802-3021



SYS-CON Featured Whitepapers
ADS BY GOOGLE